Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...

On Jan. 30, Leerink Partners analyst Daina Graybosch maintained a “Buy” rating on MRK with a price target of $118, implying a potential upside of 18.2% from current levels. The mean price ...

Daina Graybosch, Leerink Partners: Asked about WINREVAIR’s HYPERION trial outcomes. Dean Li stated the trial was stopped early due to overwhelming efficacy, reinforcing the drug’s ...

Q4 2024 Management View Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted ...

Leerink Partners analyst Daina Graybosch cautioned against too much pessimism, writing “this continued uncertainty is likely driving more downside than warranted.” The issues with Gardasil sales in ...

Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings of $11.66 per share for the year. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is ...

Introduction: Pre-harvest Sprouting (PHS) seriously affects wheat quality and yield. However, to date there have been limited reports. It is of great urgency to breed resistance varieties via ...

I am the Michael Douglas Dean of Humanities and Fine Arts and Professor of History at the University of California Santa Barbara. I research, write and teach about the lives of the enslaved as ...